Cover Image

Chronic Myeloid Leukemia with Rare e1a3 BCR-ABL Transcript

Chronic myelogenous leukemia (CML) results from neoplastic transformation of a hematopoietic stem cell. It is cytogenetically characterized by the presence of Philadelphia chromosome which results from reciprocal translocation t(9;22) that juxtaposes the ABL gene on chromosome 9 with breakpoint clus...

Full description

Saved in:

Bibliographic Details
Main Authors:	Najia Tabassum (Author), Rubina Ghani (Author), Mohammad Saboor (Author), Moinuddin Moinuddin (Author)
Format:	Book
Published:	ziauddin University, 2024-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia
by: Aypara Hasanova, et al.
Published: (2023)

BCR-ABL fusion genes and laboratory findings in patients with chronic myeloid leukemia in northeast Iran
by: Hossein Ayatollahi, et al.
Published: (2018)

BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia
by: Gustavo P. Amarante-Mendes, et al.
Published: (2022)

Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia
by: Raquel Vinhas, et al.
Published: (2017)

The proteolysis targeting chimera GMB-475 combined with dasatinib for the treatment of chronic myeloid leukemia with BCR::ABL1 mutants
by: Wu Ye, et al.
Published: (2022)

Determination of lactate dehydrogenase (LDH) and Bcr-Abl transcript in the follow-up of patients with chronic myeloid leukemia = Determinação da lactate desidrogenase (LDH) e do transcrito Bcr-Abl em pacientes com leucemia mielóide crônica
by: Roberto Iemitsu Tatakihara, et al.
Published: (2010)

Discontinuation of tyrosine kinase inhibitors based on BCR-ABL1 monitoring by digital droplet PCR in pediatric chronic myeloid leukemia
by: Yeojae Kim, et al.
Published: (2022)

I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition
by: Congying Gao, et al.
Published: (2023)

CLINICAL CASE OF TREATMENT OF A PATIENT WITH CHRONIC MYELOID LEUKEMIA WITH A MUTATION BCR-ABL Y253H AND COMORBIDITIES
by: G. Sh. Safuanova, et al.
Published: (2019)

Fluorescence in situ hybridization patterns of BCR/ABL1 fusion in chronic myelogenous leukemia at diagnosis
by: Poonam P Jain, et al.
Published: (2012)

A Novel ELISA-Based Peptide Biosensor Assay for Screening ABL1 Activity in vitro: A Challenge for Precision Therapy in BCR-ABL1 and BCR-ABL1 Like Leukemias
by: Oksana Montecchini, et al.
Published: (2021)

Association between the BCR-ABL gene transcripts and the laboratory hematological profile
by: Marcelo Braga de Oliveira, et al.
Published: (2022)

A case report of pediatric acute lymphoblastic leukemia with e8a2 BCR/ABL1 fusion transcript
by: Aleksandra Mroczkowska, et al.
Published: (2022)

Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment
by: Erin Clapper, et al.
Published: (2020)

Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts
by: Michele Massimino, et al.
Published: (2021)

PPFIA1-targeting miR-181a mimic and saRNA overcome imatinib resistance in BCR-ABL1-independent chronic myeloid leukemia by suppressing leukemia stem cell regeneration
by: Rui Su, et al.
Published: (2023)

<b>Determination of lactate dehydrogenase (LDH) and <em>Bcr-Abl</em> transcript in the follow-up of patients with chronic myeloid leukemia</b> - doi: 10.4025/actascihealthsci.v32i2.6408
by: Roberto Iemirsu Tatakihara, et al.
Published: (2010)

FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions
by: Philippa C. May, et al.
Published: (2023)

BCR-ABL1-positive acute lymphoblastic leukemia following successful treatment of acute promyelocytic leukemia: case report
by: Shuang Fu, et al.
Published: (2023)

PEG-Bottlebrush Stabilizer-Based Worm-like Nanocrystal Micelles with Long-Circulating and Controlled Release for Delivery of a BCR-ABL Inhibitor against Chronic Myeloid Leukemia (CML)
by: Huamin Liang, et al.
Published: (2022)

New Inhibitors of Bcr-Abl Based on 2,6,9-Trisubstituted Purine Scaffold Elicit Cytotoxicity in Chronic Myeloid Leukemia-Derived Cell Lines Sensitive and Resistant to TKIs
by: Thalia Delgado, et al.
Published: (2024)

Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice
by: Vicki Xie, et al.
Published: (2018)

The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study
by: Hélène Haguet, et al.
Published: (2020)

Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia
by: Rubin Cheng, et al.
Published: (2021)

Concomitant BCR-ABL1 positive chronic myelogenous leukemia emerging in a patient with MPL W515L associated primary myelofibrosis
by: Juan C. Gomez-Gelvez, MD, et al.
Published: (2016)

Targeting BCR-ABL1-positive leukaemias: a review article
by: Steven Leak, et al.
Published: (2023)

Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India
by: Nikhil Rabade, et al.
Published: (2018)

BCR/ABL positive thrombocythemia: a diagnostic dilemma
by: Lubna Zafar, et al.
Published: (2017)

Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia
by: El Rassi F, et al.
Published: (2013)

Synergistic cytotoxicity from combination of imatinib and platinum-based anticancer drugs specifically in Bcr-Abl positive leukemia cells
by: Yuming Wei, et al.
Published: (2015)

A Bcr-Abl Inhibitor GNF-2 Attenuates Inflammatory Activation of Glia and Chronic Pain
by: Gyun Jee Song, et al.
Published: (2019)

A Novel Naphthoquinone-Coumarin Hybrid That Inhibits BCR-ABL1-STAT5 Oncogenic Pathway and Reduces Survival in Imatinib-Resistant Chronic Myelogenous Leukemia Cells
by: Patricia Martín-Rodríguez, et al.
Published: (2019)

Distribution of common BCR-ABL fusion transcripts and their impact on treatment response in Imatinib treated CML patients: A study from India
by: Sudha Sazawal, et al.
Published: (2019)

Analytical study of RUNX1-RUNXT1, PML-RARA, CBFB-MYH11, BCR-ABL1p210, and KMT2-MLLT3 in Mexican children with acute myeloid leukemia: A multicenter study of the Mexican interinstitutional group for the identification of the causes of childhood leukemia (MIGICCL)
by: Omar Sepúlveda-Robles, et al.
Published: (2022)

Karakteristik Klinis Pasien Leukemia Limfoblastik Akut (LLA) dengan Fusi Gena TELAML1, BCR-ABL, dan E2A-PBX1
by: Sri Mulatsih, et al.
Published: (2016)

Dedifferentiation of B-lymphoblastic leukemia/lymphoma with t(9;22) BCR::ABL1 to an undifferentiated neoplasm with strong keratin expression in a patient receiving blinatumomab
by: Krasimira A. Rozenova, et al.
Published: (2023)

Frequency of BCR-ABL Gene Translocation in B-ALL Patients Associated with Clinicopathological Parameters
by: Amna Qamar, et al.
Published: (2024)

Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation
by: Liang Jiang, et al.
Published: (2021)

Pharmacophore mapping: Prediction of BCR-ABL kinase inhibitory activity of α-benzylthio chalcones
by: Richa Bajaj, et al.
Published: (2014)

Mechanistic Insights Into Co-Administration of Allosteric and Orthosteric Drugs to Overcome Drug-Resistance in T315I BCR-ABL1
by: Hao Zhang, et al.
Published: (2022)